View a list of current clinical trials on heart attack risk, abnormal lipid levels and more.

Continuing a long tradition of research and pioneering advances in preventive cardiovascular medicine, Penn's Preventive Cardiovascular Program leads the development and evaluation of novel therapeutic, diagnostic, and prognostic approaches to atherosclerotic disease. Patients may be eligible for any clinical trial if certain criteria is met.

Clinical trials in which we are currently enrolling patients include:

Abnormal LDL-cholesterol

Evaluation of Abnormal Plasma Lipid Levels

National Characterization of Patients with Severe Hypercholesterolemia

Characterizing PCSK9 in Patients Eligible for LDL Apheresis

Abnormal HDL-cholesterol

Evaluation of Abnormal Plasma Lipid Levels

National Characterization of Patients with Severe Hypercholesterolemia

Characterizing PCSK9 in Patients Eligible for LDL Apheresis

Safety and Efficacy of REGN727 in Familial Hypercholesterolemia

Biochemical Characteristics of Elevated HDL and Coronary Heart Disease

Mechanistic Study of HDL Kinetics in Patients with Elevated HDL

Genetics of High HDL

Effect of Low HDL on Blood Sugar

Abnormal triglycerides

Evaluation of Abnormal Plasma Lipid Levels

Efficacy and Safety of Epanova® in Severe Hypertriglyceridemia

Heart attack / Coronary disease

Biochemical Characteristics of Elevated HDL and Coronary Heart Disease

Mechanistic Study of HDL Kinetics in Patients with Elevated HDL

The Complex Genetics Initiative

Peripheral vascular disease

Sodium Nitrite in Diabetic Patients with Peripheral Artery Disease

Genetic Information to Guide Anticoagulation Therapy

Safety and Efficacy of GSK1278863 for Peripheral Artery Disease

Genetic Causes of Varicose Veins

MRI Examination for Peripheral Artery Disease

Diabetes / High blood glucose

Sodium Nitrite in Diabetic Patients with Peripheral Artery Disease

Penn Diabetes Heart Study

High blood pressure

Lifestyle Modification in Blood Pressure Study (LIMBS)

Psoriasis cardiovascular evaluation

A Descriptive Study to Evaluate Cardiometabolic Risk Factors in Patients with Psoriasis (PSO-D)

A Descriptive Study to Evaluate Subclinical Atherosclerosis by FDG PET CT in Patients with Psoriasis, Rheumatoid Arthritis and Psoriatic Arthritis (PSO-CVD)

The Vascular Inflammation in Psoriasis Trial (VIP)

The Vascular Inflammation in Psoriasis Trial in patients treated with Ustekinumab (VIP-2)

Share This Page: